LIU Zhi-Hui, SHAO Yun-Chao1, CHEN Hong-Hong2, SHI De-Yuan1, CHEN Tong-Yi1, CUI Da-Fu*
( Institute of Biochemistry and Cell Biology, Shanghai
Institute for Biological Sciences, the Chinese Academy of Sciences, Shanghai
200031, China;
1 Department of Orthopaedics, Zhongshan Hospital, Fudan University,
Shanghai 200030, China;
2 Shangshai Yi Zhong Biological Technique Co., Ltd., Shanghai
201203, China )
Abstract Osteogenic growth peptide (OGP) has been
synthesized through Fmoc solid phase synthesis procedure. The purity of
synthetic OGP (sOGP) is over 98.6% identified by HPLC, the amino acid sequence
and electro-spray mass spectroscopy are consistent with theoretical values. The
synergetic effect of sOGP with recombinant human granulocyte-colony stimulating
factor (rhG-CSF) on the hematopoiesis was investigated in normal mice. To assess
the synergy of sOGP with rhG-CSF, two schemes were designed. In one scheme
rhG-CSF was used at the last 8 days of a 13-day treatment with sOGP, while in
the other one both cytokines were given concurrently for 10 days [sOGP, 0.5
nmol/day (mouse); rhG-CSF, 2 nmol/day (mouse)]. Both schemes showed that sOGP
remarkably synergized with rhG-CSF on increment of white blood cell number and
lymphocyte number in peripheral blood without any change of red blood cell and
platelet counts. Quantitative differential analysis of bone marrow and
histological examination of the spleen and sternum showed that sOGP plus
rhG-CSF did not cause abnormal hyperplasia, so sOGP is a very hopeful new drug
to improve the effectiveness of clinical used rhG-CSF.
Key words OGP; G-CSF; synergy;
hematopoiesis; solid phase synthesis
Corresponding author: Tel, 86-21-64315030-5262; Fax, 86-21-64338357; e-mail, [email protected]